We have used technical developments in treatment planning and on site imaging to develop protocols in precision radiotherapy especially for lung cancer and prostate cancer. Both dose escalation resulting in better tumor control and better dose shaping resulting in better treatment tolerance are being pursued. Main efforts concentrate on Extracranial Stereotactic Radiotherapy and Integrated Boost concepts.
Robotic guidance of the treatment process as well as integration of advanced functional imaging (Bold MRI and hypoxic Pet Tracers) is the current focus of our work.
Holubyev K, Gainey M, Bratengeier K, Polat B, Flentje M Generation of prostate IMAT plans adaptable to the inter-fractional changes of patient geometry. Phys Med Biol. 2014; 59(8):1947-1962
Guckenberger M, Lawrenz I, Flentje M. Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Strahlenther Onkol. 2014;190(1):48-53
Guckenberger M, Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol. 2013 ;109(1):13-20.
Wilbert J, Baier K, Hermann C, Flentje M, Guckenberger M. Accuracy of real-time couch tracking during 3-dimensional conformal radiation therapy, intensity modulated radiation therapy, and volumetric modulated arc therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 ;85(1):237-42
Schmitt P, Jakob PM, Kotas M, Flentje M, Haase A, Griswold MA T-one insensitive steady state imaging: a framework for purely T2-weighted TrueFISP. Magn Reson Med. 2012 ;68(2):409-20